The High-Stakes Partnership: Can Elixirgen Therapeutics and Nippon Shinyaku Deliver on Duchenne Muscular Dystrophy Treatment?
As the pharmaceutical industry continues to evolve, the partnership between Elixirgen Therapeutics and Nippon Shinyaku for the development of EXG-7001, a treatment for Duchenne Muscular Dystrophy
3 months ago